Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leadership team will attend and participate in the 2025 BIO International Convention, taking place June 16-19, 2025, in Boston, Massachusetts. During the conference, Processa’s CEO, Georg Ng and Dr. David Young, President R&D will conduct one-on-one meetings with potential partne ...